Clinical Trial Update: A Comparative Study of KW-2246 [Phase 3]

View source ↗

Summary

Phase 3 comparative trial of KW-2246 for cancer-related breakthrough pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• KW-2246

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Cancer Related Pain (Breakthrough Pain) | Phase 3 | Status: COMPLETED